These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34477809)

  • 1. Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink.
    Blumenthal KG; Phadke NA; Bates DW
    JAMA; 2021 Oct; 326(14):1375-1377. PubMed ID: 34477809
    [No Abstract]   [Full Text] [Related]  

  • 2. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
    Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working.
    Navar AM; McNally E; Yancy CW; O'Gara PT; Bonow RO
    JAMA Cardiol; 2021 Oct; 6(10):1117-1118. PubMed ID: 34185044
    [No Abstract]   [Full Text] [Related]  

  • 4. Developing standard safety outcomes for COVID-19 vaccines.
    Buttery JP
    Vaccine; 2021 May; 39(22):3025-3027. PubMed ID: 33888324
    [No Abstract]   [Full Text] [Related]  

  • 5. Planning for COVID-19 vaccines safety surveillance.
    Kochhar S; Salmon DA
    Vaccine; 2020 Sep; 38(40):6194-6198. PubMed ID: 32684499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data.
    Hashimoto T; Ozaki A; Bhandari D; Sawano T; Sah R; Tanimoto T
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34128049
    [No Abstract]   [Full Text] [Related]  

  • 7. 'COVID vaccine arm' may present after both mRNA vaccines vaccination.
    Gregoriou S; Kleidona IA; Tsimpidakis A; Nicolaidou E; Stratigos A; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e867-e868. PubMed ID: 34416053
    [No Abstract]   [Full Text] [Related]  

  • 8. Positive aspects of the mRNA platform for SARS-CoV-2 vaccines.
    Hajissa K; Mussa A
    Hum Vaccin Immunother; 2021 Aug; 17(8):2445-2447. PubMed ID: 33830862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 vaccines and pregnancy: What do we know?
    Cottin J; Benevent J; Khettar S; Lacroix I
    Therapie; 2021; 76(4):373-374. PubMed ID: 34238585
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
    Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
    Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine].
    Bekkali N; Allard T; Lengellé C; Estève E
    Therapie; 2021; 76(4):364-365. PubMed ID: 34272069
    [No Abstract]   [Full Text] [Related]  

  • 12. COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says.
    Chen G; Li X; Sun M; Zhou Y; Yin M; Zhao B; Li X
    Front Immunol; 2021; 12():669010. PubMed ID: 34093567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localized cutaneous reaction to an mRNA COVID-19 vaccine.
    Edriss M; Farshchian M; Daveluy S
    J Cosmet Dermatol; 2021 Aug; 20(8):2380-2381. PubMed ID: 34129749
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Skowronski DM; De Serres G
    N Engl J Med; 2021 Apr; 384(16):1576-1577. PubMed ID: 33596348
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders.
    Rosman Y; Lavi N; Meir-Shafrir K; Lachover-Roth I; Cohen-Engler A; Mekori YA; Confino-Cohen R
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3487-3489. PubMed ID: 34224924
    [No Abstract]   [Full Text] [Related]  

  • 17. SARS-CoV-2 mRNA Vaccine Attitudes as Expressed in U.S. FDA Public Commentary: Need for a Public-Private Partnership in a Learning Immunization System.
    Weitzman ER; Sherman AC; Levy O
    Front Public Health; 2021; 9():695807. PubMed ID: 34336774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC28. PubMed ID: 33646836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
    Sun H
    N Engl J Med; 2021 Oct; 385(16):1535-1536. PubMed ID: 34496197
    [No Abstract]   [Full Text] [Related]  

  • 20. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.